Emcure IPO to stick hefty price tag on pharma firm, hand 26% return to Bain

Pune-based Emcure Pharmaceuticals’ initial public offering (IPO) will make it the most expensive firm among peers and hand out 26% annualised return on paper to US private equity company Bain Capital, show VCCircle estimates. Emcure recently filed draft papers for an IPO worth Rs 4,000 crore is expected to bestow a ......